4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

At the Jefferies London Healthcare Conference, 4D Molecular Therapeutics presented an adaptable genetic-medicine pipeline focused on ophthalmology and pulmonology, highlighting lead asset 4D-150 for wet AMD and DME and inhaled 4D-710 for cystic fibrosis. Management said 4D-150 shows clear efficacy and safety with the potential to dramatically reduce treatment burden in a roughly $17 billion retina market, benefits from low cost of goods and integration into existing retina practice workflows that could aid commercial adoption and pricing flexibility. 4D-710 delivers a CFTR transgene with reproducible airway transduction and gene expression and a Phase I update is expected in December; the company also acknowledged broader gene-therapy limitations while arguing its approach mitigates key commercialization and manufacturing constraints.

Analysis

At the Jefferies London Healthcare Conference on November 18, 2025, 4D Molecular Therapeutics management (CEO David Kirn and CCO Chris Simms) reiterated a two-pronged pipeline led by 4D-150 for wet AMD and DME and inhaled 4D-710 for cystic fibrosis. Management characterized 4D-150 as demonstrating safety and “clear efficacy” with the ability to dramatically reduce treatment burden in a roughly $17 billion retina market, and emphasized low cost of goods and seamless fit into existing retina practice workflows as commercialization advantages.

4D-710 was presented as an aerosol-delivered CFTR transgene therapy with reproducible airway transduction and gene expression, and the company has signaled a Phase I program update in December. Management acknowledged broader gene-therapy limitations but argued their approach mitigates manufacturing and commercial constraints, implying differentiated operational economics versus typical gene therapies.

Market signals show a moderately positive reception (sentiment score 0.45) but a modest immediate market impact (0.35), indicating investor interest with remaining caution. Near-term catalysts are the December Phase I update for 4D-710 and any further clinical details the company provides on 4D-150; primary risks are binary clinical/regulatory outcomes, payer acceptance despite low COGS, and execution on commercialization strategy.

Key Decisions for Investors

• Consider establishing a sized, risk-capital position ahead of the December Phase I update for 4D-710 if comfortable with binary clinical risk, but limit exposure given the program’s early-stage nature
• Monitor forthcoming detailed efficacy and safety data for 4D-150 and management’s commercialization plans and pricing assumptions—positive confirmation could materially re-rate the stock given the $17 billion addressable market and low cost of goods
• Use stop-losses or hedges to manage downside from adverse clinical or regulatory news, and reassess position sizing after the December update and any further 4D-150 disclosures